Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Condition: Interstitial Lung Disease Interventions: Drug: efzofitimod 450 mg; Drug: efzofitimod 270 mg; Drug: Placebo Sponsor: aTyr Pharma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials